chloroquine/povraćanje

Veza se sprema u međuspremnik

Odaberite vrstu sortiranja

Page 1 od 18 rezultati

Efficacy of Sunlight Activated Synthetic Porphyrin in COVID-19 Infected Patients

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Efficacy of Sunlight Activated Synthetic Porphyrin in COVID-19 Infected Patients (SnPPIX) Official Title: Efficacy of Based MRI Contrast Media Against Covid-19 _____________________________________________________________________________________________

Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Selected Drugs Hydroxychloroquine (an analog of chloroquine) has been demonstrated to have an anti-SARS-CoV activity in vitro. Hydroxychloroquine clinical safety profile is better than that of chloroquine (during long-term use) and allows higher daily dose and has fewer concerns about drug-drug

Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Humanity has been experiencing a new pandemic of the SARS Coronavirus-19 virus (SARS-CoV-2) since December 2019, causing the disease known as COVID-19. As of March 23, 2020, there have been 382,341 documented episodes of infection worldwide, of which 16,567 have died. An important limitation in the

Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Inclusion criteria: - Adult patients (>18 years) - Confirmed COVID-19 infection by real-time PCR from a respiratory or other body sample within 48 hours of testing. - Mild to moderate infection or asymptomatic patients with comorbidities: Symptomatic patients with fever >37.9ºC or cough or dyspnea

Determining the Impact of Scaling up Mass Testing, Treatment and Tracking on Malaria Prevalence in Ghana

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Background Malaria continues to pose a serious burden to the local populations in sub-Sahara Africa. Several efforts have been made to scale up interventions that work such as preventing man-vector contact, intermittent preventive therapy, seasonal malaria chemoprophylaxis as well as TTT for febrile

TES Artemether-lumefantrine for Pf and Chloroquine (CQ) for Pv

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

1. BACKGROUND In 2002, the Philippines changed its antimalarial drug policy to the combination treatment, CQ+ Sulphadoxine-pyrimethamine (SP) as 1st-line treatment and artemether-lumefantrine as 2nd-line treatment. The Department of Health (DOH) prescribed the use of artemether-lumefantrine (AL)

Impact of Scaling up Mass Testing, Treatment and Tracking on Malaria Prevalence Among Children

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Introduction/Rationale The World Health Organization (WHO) in 2010 reported that malaria was endemic in 96 countries reflecting an improvement of the situation of 2005 where it was endemic in 106 countries. Malaria morbidity and mortality remain a serious problem in sub Saharan Africa especially in

Pre-delivery Administration of Azithromycin to Prevent Neonatal Sepsis & Death

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

other data elements, such as eligibility criteria or outcome measures. (Limit: 32,000 characters) Project title: Pre-delivery administration of azithromycin to prevent neonatal sepsis and death: a phase III double-blind randomized clinical trial Acronym: PregnAnZI-2 LIST OF INVESTIGATORS Chief

Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Malaria incidence has increased two- to three-folds over the past four decades, and nearly half the world's population now lives in regions endemic for malaria: In Asia, Africa, and South America. A global annual estimate of 300-500 clinical cases of malaria and mortality in the range of 1-2 million

G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

1. Screening All patients registering for outpatient services in the outpatient department will undergo routine investigation. When malaria is suspected, a thick and thin blood smear will be obtained for microscopic diagnosis of Plasmodium vivax or a malaria RDT undertaken. After the diagnosis is

Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine for Plasmodium Vivax Infection

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

1. OBJECTIVE- To assess the efficacy of co-administered chloroquine+primaquine (CQ+PQ) vs.CQ alone (PQ being postponed up to day 28 of CQ therapy) as a schizontocidal therapy (28-day follow-up) and as radical cure among uncomplicated P. vivax malaria (6-month follow-up). Specifically: - To measure

Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Uncomplicated Malaria in South Kivu, DR Congo

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

3.1 STUDY DESIGN Children with uncomplicated malaria meeting the inclusion criteria will be enrolled (after their parent/caretaker has given informed consent), treated on site with the drugs under evaluation and followed-up for a period of 42 days. Drugs will be given under direct supervision,

Evaluating the Efficacy of Chloroquine for the Treatment of Plasmodium Vivax Infections in Central Vietnam

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

3.1 Study Design This study is designed as a 42-day drug efficacy study to evaluate clinical and parasitological responses after treatment of P.vivax malaria infections. Symptomatic patients with P. vivax mono-infections, meeting the study criteria, will be enrolled into the study, and treated with

Improving Anti-malarial Treatment Options in Guinea-Bissau - Part A

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Background Plasmodium falciparum causes malaria and approximately 665 000 deaths each year. Previously chloroquine (CQ) and sulphadoxine-pyrimethamine were the principle drugs for the treatment of malaria. Due to widespread resistance to these drugs1, the World Health Organization recommends that P.

Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse

Samo registrirani korisnici mogu prevoditi članke

Prijavite se / prijavite se

Plasmodium vivax represents 50-80% of all malarial cases in Latin America and South East Asia. It is able to establish a dormant liver stage called the hypnozoite. Hypnozoite activation after initial infection can cause a relapse. Currently the only widely available drug is primaquine which requires

Prethodni
1
2
Sljedeći

Pridružite se našoj
facebook stranici

Herbal & Natural Medicine

Najkompletnija baza ljekovitog bilja potpomognuta naukom

Radi na 55 jezika
Biljni lijekovi potpomognuti naukom
Prepoznavanje biljaka po slici
Interaktivna GPS karta - označite bilje na lokaciji (uskoro)
Pročitajte naučne publikacije povezane sa vašom pretragom
Pretražite ljekovito bilje po učincima
Organizirajte svoja interesovanja i budite u toku sa istraživanjem vijesti, kliničkim ispitivanjima i patentima

Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Sve informacije temelje se na objavljenim naučnim istraživanjima